Literature DB >> 11295468

Molecular profile of a human monoclonal antibody Fab fragment specific for Epstein-Barr virus gp350/220 antigen.

F Bugli1, R Bastidas, D R Burton, R A Williamson, M Clementi, R Burioni.   

Abstract

Experimental evidence indicates Epstein Barr virus (EBV) envelope glycoprotein gp350/220 elicits a potent virus neutralizing response in the infected human host that may play an important role in restricting viral pathogenesis. In this study, we report the molecular cloning in combinatorial phage display vectors, of the IgG1 repertoire of an individual naturally infected with EBV, and describe the recovery and characterization of a monoclonal antibody recognizing gp350/220. A detailed understanding of the human antibody response in EBV infection will identify antibodies of potential use in anti-viral prophylaxis and will advance the production of more effective vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295468     DOI: 10.1016/s0198-8859(01)00216-6

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  2 in total

1.  Production and characterization of a human recombinant monoclonal Fab fragment specific for influenza A viruses.

Authors:  Alessandra Desogus; Roberto Burioni; Angela Ingianni; Francesca Bugli; Raffaello Pompei; Giovanni Fadda
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies.

Authors:  Rachael E Whaley; Sarah Ameny; Tanvi Arkatkar; Aaron Seese; Abigail Wall; Iram Khan; Joseph J Carter; Erin M Scherer; David J Rawlings; Denise A Galloway; M Juliana McElrath; Kristen W Cohen; Andrew T McGuire
Journal:  J Immunol Methods       Date:  2020-10-15       Impact factor: 2.287

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.